Literature DB >> 35483735

Learnings from Throwing Paint at the Wall for COVID-19 with an SGLT2 Inhibitor.

Katherine R Tuttle1,2.   

Abstract

Entities:  

Keywords:  COVID-19; GFR; SARS-CoV-2; SGLT2; acute kidney injury; dapagliflozin; pandemic; safety; sodium-glucose cotransporter 2

Mesh：

Substances：

Year:  2022        PMID： 35483735      PMCID： PMC9269582          DOI： 10.2215/CJN.03250322

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  10 in total

Review 1.  SGLT2 inhibitors may offer benefit beyond diabetes.

Authors:  Amy Kang; Meg J Jardine
Journal:  Nat Rev Nephrol       Date:  2021-02       Impact factor: 28.314

2.  Changing the Trajectory of Heart Failure and Kidney Disease: A Call for Action.

Authors:  Janani Rangaswami; Vivek Bhalla; Glenn M Chertow; Robert A Harrington; Alexander Staruschenko; Katherine Tuttle; Eugene Braunwald
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-01       Impact factor: 10.614

3.  Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.

Authors:  Hiddo J L Heerspink; Remo H M Furtado; Otavio Berwanger; Gary G Koch; Felipe Martinez; Omar Mukhtar; Subodh Verma; Samvel B Gasparyan; Fengming Tang; Sheryl L Windsor; Vicente Cés de Souza-Dantas; Mildren Del Sueldo; Robert Frankel; Ali Javaheri; Rafael A Maldonado; Caryn Morse; Marco Mota-Gomes; Douglas Shemin; Osvaldo Lourenço Silva; Alexandre Pereira Tognon; Marcel Twahirwa; Joan Buenconsejo; Russell Esterline; Jan Oscarsson; Philip Ambery; Anna Maria Langkilde; Mikhail N Kosiborod
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-28       Impact factor: 10.614

4.  SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Authors:  Katherine R Tuttle; Frank C Brosius; Matthew A Cavender; Paola Fioretto; Kevin J Fowler; Hiddo J L Heerspink; Tom Manley; Darren K McGuire; Mark E Molitch; Amy K Mottl; Leigh Perreault; Sylvia E Rosas; Peter Rossing; Laura Sola; Volker Vallon; Christoph Wanner; Vlado Perkovic
Journal:  Am J Kidney Dis       Date:  2020-10-26       Impact factor: 8.860

5.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Authors:  Brendon L Neuen; Tamara Young; Hiddo J L Heerspink; Bruce Neal; Vlado Perkovic; Laurent Billot; Kenneth W Mahaffey; David M Charytan; David C Wheeler; Clare Arnott; Severine Bompoint; Adeera Levin; Meg J Jardine
Journal:  Lancet Diabetes Endocrinol       Date:  2019-09-05       Impact factor: 32.069

6.  Misguided Use of Hydroxychloroquine for COVID-19: The Infusion of Politics Into Science.

Authors:  Michael S Saag
Journal:  JAMA       Date:  2020-12-01       Impact factor: 56.272

7.  Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.

Authors:  Hiddo J L Heerspink; C David Sjöström; Niels Jongs; Glenn M Chertow; Mikhail Kosiborod; Fan Fan Hou; John J V McMurray; Peter Rossing; Ricardo Correa-Rotter; Raisa Kurlyandskaya; Bergur V Stefansson; Robert D Toto; Anna Maria Langkilde; David C Wheeler
Journal:  Eur Heart J       Date:  2021-03-31       Impact factor: 29.983

8.  Retraction to: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection.

Authors:  Andrew Hill; Anna Garratt; Jacob Levi; Jonathan Falconer; Leah Ellis; Kaitlyn McCann; Victoria Pilkington; Ambar Qavi; Junzheng Wang; Hannah Wentzel
Journal:  Open Forum Infect Dis       Date:  2022-02-05       Impact factor: 3.835

9.  Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Mikhail N Kosiborod; Russell Esterline; Remo H M Furtado; Jan Oscarsson; Samvel B Gasparyan; Gary G Koch; Felipe Martinez; Omar Mukhtar; Subodh Verma; Vijay Chopra; Joan Buenconsejo; Anna Maria Langkilde; Philip Ambery; Fengming Tang; Kensey Gosch; Sheryl L Windsor; Emily E Akin; Ronaldo V P Soares; Diogo D F Moia; Matthew Aboudara; Conrado Roberto Hoffmann Filho; Audes D M Feitosa; Alberto Fonseca; Vishnu Garla; Robert A Gordon; Ali Javaheri; Cristiano P Jaeger; Paulo E Leaes; Michael Nassif; Michael Pursley; Fabio Serra Silveira; Weimar Kunz Sebba Barroso; José Roberto Lazcano Soto; Lilia Nigro Maia; Otavio Berwanger
Journal:  Lancet Diabetes Endocrinol       Date:  2021-07-21       Impact factor: 32.069

10.  Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.

Authors:  Eric J Rubin
Journal:  N Engl J Med       Date:  2020-06-02       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.